secwatch.observer — SEC 8-K summary
======================================

Issuer:     Traws Pharma, Inc. (TRAW)
CIK:        0001130598
Form:       8-K
Filed at:   2025-06-30T23:59:59+00:00
Accession:  0001104659-25-063793
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Traws Pharma submits Phase 2 protocols for bird flu and COVID drugs; requests FDA meeting
--------------------------------------------------------------------------------

- Submitted HREC Phase 2 protocol for tivoxavir marboxil (TXM) to treat H5N1 bird flu and seasonal influenza.
- Submitted Type D FDA meeting request to discuss accelerated approval for TXM under the Animal Rule.
- Submitted HREC Phase 2 protocol for ratutrelvir in acute COVID, including PAXLOVID-ineligible patients, with rebound and Long COVID assessments.
- Cash and equivalents of $15.9M as of March 31, 2025, expected to fund operations into Q1 2026.
- Continuing discussions with BARDA regarding strategic stockpile inclusion for TXM.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1130598/000110465925063793/0001104659-25-063793-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1130598/000110465925063793/tm2519404d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-063793

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer